'Thank God' Kiran Mazumdar Shaw did not become a doctor: When Dr Devi Shetty shared a life lesson from Biocon founder's inspiring journey

Sometimes, the most powerful success stories begin with a rejection that feels devastating in the moment. What looks like an ending can quietly become the starting point of something far bigger than imagined. One of India’s most respected surgeons reflected on how a single missed opportunity in medicine eventually reshaped the future of an entire industry. His story about Kiran Mazumdar Shaw turns disappointment into direction and failure into unexpected impact.

While attending an event at the Indian Institute of Management Bangalore, Devi Shetty, in 2015, founder and chairman of Narayana Health, shared an inspiring reflection of his owna and Kiran Mazumdar-Shaw's journey. He shared a personal story from his early years in England. He recalled being confident about securing a registrar position at Southampton Hospital after completing a year there, especially since professional connections had informally indicated that the role would likely be his. However, during the interview process, another candidate was selected. The rejection deeply affected him, as he had already imagined a future there with his family. Standing at a railway station, he called his wife to tell her they would have to return to India with their two children. Instead of reacting with disappointment, his wife calmly reassured him, saying that perhaps life had something better planned for him ahead.

What did he say about Kiran Mazumdar Shaw?

He spoke about how her original dream was to become a doctor and how she had fully expected to secure admission into one of the prestigious medical colleges in Bengaluru. When that did not happen, it brought deep disappointment, as it felt like a closed door on a lifelong ambition.


However, what followed that setback changed everything. Instead of stepping away from the world of healthcare, she chose to approach it from a different angle. She redirected her intent from treating patients directly to addressing a much larger problem: access to affordable medicine. That shift in thinking eventually led her to build Biocon, a company that would go on to transform the biotechnology landscape in India.

Devi Shetty highlighted how this redirection had an impact far beyond what a traditional medical career might have achieved. He pointed out that today, millions of people living with diabetes are able to access insulin at affordable prices because of the work done by Kiran Mazumdar-Shaw. In his reflection, he suggested that sometimes what appears to be a personal setback can actually become a turning point for larger societal change. His exact words were, "So we should all thank God, and the country should thank God that Kiran didn’t get into medical college."

He went on to express that had she become a doctor in the conventional sense, she might have served individual patients in a clinical setting, treating a limited number of people over her lifetime. Instead, by not entering medical college and choosing a different path, she ended up building something that impacts millions. His remark carried a striking sentiment, suggesting that in a broader sense, it is worth acknowledging how this unexpected turn ultimately benefited the country.

About Kiran Mazumdar-Shaw

She is a first-generation entrepreneur and global business leader with more than four decades of experience in biotechnology. She began her entrepreneurial journey in 1978 from a garage in India, driven by a strong belief in making healthcare more accessible and affordable. Under her leadership, Biocon has grown into a major player in the global biotech space, focused on delivering cost-effective medicines to patients worldwide.

Her educational background

Her academic background reflects a diverse and global education. She holds a B.Sc. in Zoology (Hons.) from Bangalore University and a postgraduate diploma in Malting and Brewing from the Ballarat Institute of Advanced Education in Melbourne, Australia. Over the years, she has also been honoured with multiple honorary doctorates from institutions including Concordia University in Canada, Deakin University in Australia, Heriot-Watt University and the University of Glasgow in the UK, among others, along with Indian institutions such as Presidency University and Bennett University.

According to Forbes, her estimated net worth stands at around Rs 30,000 crore, reflecting both her business success and long-term impact in the biotech sector.

Her successor

Recently, she also shared a personal update on X, noting that Claire Mazumdar, a 37-year-old biotech specialist and founder-CEO of Bicara Therapeutics, a NASDAQ-listed company incubated by Biocon, would eventually transition into her role at the appropriate time. She mentioned that she is not planning to step away from her responsibilities yet, signalling continuity in leadership and vision.


Claire Mazumdar herself brings strong academic and professional credentials to her role. She holds a degree in Biological Engineering from the Massachusetts Institute of Technology, an MBA from Stanford Graduate School of Business, and a PhD in Cancer Biology from Stanford School of Medicine, reflecting a deep foundation in science, business, and research.